These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26089640)

  • 21. DHA regulates angiogenesis and improves the efficiency of CDDP for the treatment of lung carcinoma.
    Zhang JL; Wang Z; Hu W; Chen SS; Lou XE; Zhou HJ
    Microvasc Res; 2013 May; 87():14-24. PubMed ID: 23466284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
    Lu GS; Li M; Xu CX; Wang D
    Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
    Zhao R; Zhou S; Xia B; Zhang CY; Hai P; Zhe H; Wang YY
    BMC Cancer; 2016 Jul; 16():491. PubMed ID: 27431492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of a protein kinase C inhibitor combined with cisplatin on non-small cell lung cancer].
    Gao ZQ; Han BH; Sha HF; Shi ZY; Yang XH; Feng JX
    Zhonghua Jie He He Hu Xi Za Zhi; 2010 Apr; 33(4):284-8. PubMed ID: 20646461
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ginkgetin derived from Ginkgo biloba leaves enhances the therapeutic effect of cisplatin via ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR wild-type non-small-cell lung cancer.
    Lou JS; Zhao LP; Huang ZH; Chen XY; Xu JT; Tai WC; Tsim KWK; Chen YT; Xie T
    Phytomedicine; 2021 Jan; 80():153370. PubMed ID: 33113504
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Small-molecule inhibition of APE1 induces apoptosis, pyroptosis, and necroptosis in non-small cell lung cancer.
    Long K; Gu L; Li L; Zhang Z; Li E; Zhang Y; He L; Pan F; Guo Z; Hu Z
    Cell Death Dis; 2021 May; 12(6):503. PubMed ID: 34006852
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.
    Aftab BT; Dobromilskaya I; Liu JO; Rudin CM
    Cancer Res; 2011 Nov; 71(21):6764-72. PubMed ID: 21896639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dendrobine targeting JNK stress signaling to sensitize chemotoxicity of cisplatin against non-small cell lung cancer cells in vitro and in vivo.
    Song TH; Chen XX; Lee CK; Sze SC; Feng YB; Yang ZJ; Chen HY; Li ST; Zhang LY; Wei G; Shi J; Xu K; Ng TB; Zhu LL; Zhang KY
    Phytomedicine; 2019 Feb; 53():18-27. PubMed ID: 30668397
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cationic liposome-mediated nitric oxide synthase gene therapy enhances the antitumor effects of cisplatin in lung cancer.
    Ye S; Yang W; Wang Y; Ou W; Ma Q; Yu C; Ren J; Zhong G; Shi H; Yuan Z; Su X; Zhu W
    Int J Mol Med; 2013 Jan; 31(1):33-42. PubMed ID: 23128378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JARID2 promotes stemness and cisplatin resistance in non-small cell lung cancer via upregulation of Notch1.
    Wang Q; Wu J; Wei H; Huang H; Huang Y; Fang H; Gong X; Sun J; Wu Y; Lei C; Yu J; Hu D
    Int J Biochem Cell Biol; 2021 Sep; 138():106040. PubMed ID: 34246759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metuzumab enhanced chemosensitivity and apoptosis in non-small cell lung carcinoma.
    Feng F; Wang B; Sun X; Zhu Y; Tang H; Nan G; Wang L; Wu B; Huhe M; Liu S; Diao T; Hou R; Zhang Y; Zhang Z
    Cancer Biol Ther; 2017 Jan; 18(1):51-62. PubMed ID: 28055291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synergistic anticancer effects of ginsenoside CK and gefitinib against gefitinib-resistant NSCLC by regulating the balance of angiogenic factors through HIF-1α/VEGF.
    Song X; Wang L; Cai P; Xu Y; Liu Q; Fan D
    Toxicol Appl Pharmacol; 2024 May; 486():116938. PubMed ID: 38642809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic anticancer effect of combined use of Trichosanthes kirilowii with cisplatin and pemetrexed enhances apoptosis of H1299 non-small-cell lung cancer cells via modulation of ErbB3.
    Ku JM; Hong SH; Kim HI; Kim MJ; Kim SK; Kim M; Choi SY; Park J; Kim HK; Kim JH; Seo HS; Shin YC; Ko SG
    Phytomedicine; 2020 Jan; 66():153109. PubMed ID: 31790894
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
    Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
    Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
    Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
    Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymoquinone and cisplatin as a therapeutic combination in lung cancer: In vitro and in vivo.
    Jafri SH; Glass J; Shi R; Zhang S; Prince M; Kleiner-Hancock H
    J Exp Clin Cancer Res; 2010 Jul; 29(1):87. PubMed ID: 20594324
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
    Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
    Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.